| Sex (N=849) |
Male |
442 (52%) |
| Female |
407 (48%) |
| Sex-ratio (male/female) |
1,1 |
| Age group (N=854) |
[0-1] |
149 (17%) |
| [1-5] |
257 (30%) |
| [5-10] |
352 (41%) |
| [10-14] |
96 (11%) |
| Average time of monitoring |
20 ± 30 month |
|
| Circonstances of screening (N=321) |
PMTCT |
112 (35%) |
| Clinical suspicion |
175 (55%) |
| Volontary test* |
34 (11%) |
| Type of HIV (N=623) |
HIV1 |
621(99.7%) |
| HIV2 |
0 (0%) |
| HIV1+2 |
2 (0.3%) |
| WHO clinical stages (N=517) |
Stage 1 |
149 (29%) |
| Stage 2 |
112 (22%) |
| Stage 3 |
184 (36%) |
| Stage 4 |
72 (14%) |
| T4 lymphocytes number (N=624) |
Average for children 0-5 years |
635±528 |
| Average for children over 5 years |
312±275 |
| Therapeutic regimens (N=854) |
D4T 3TC NVP |
528(61.8%) |
| AZT 3TC NVP |
251(29.4%) |
| AZT 3TC EFV |
25 (2.9%) |
| AZT 3TC ABC |
2 (0.2%) |
| ABC DDI LPV/r |
21 (2.5%) |
| ABC 3TC LPV/r |
1 (0.1%) |
| AZT 3TC LPV/r |
22 (2.6%) |
| TDF 3TC LPV/r |
4 (0.5%) |
| Repartition of children in cohorts |
2007 cohort |
103(12.1%) |
| 2008 cohort |
68 (8%) |
| 2009 cohort |
219(25.6%) |
| 2010 cohort |
293(34.3%) |
| Unknown HAART initiation date |
171 (20%) |
